ESC 365 - Early commencement of tolvaptan therapy improves clinical outcomes in heart failure patients with preserved function of renal vasopressin V2 receptors

ESC Premium Access

Early commencement of tolvaptan therapy improves clinical outcomes in heart failure patients with preserved function of renal vasopressin V2 receptors

Session: Poster Session 1 - Chronic heart failure – Treatment

Topic: Pharmacotherapy

Speaker: Doctor T. Noto (Sapporo, JP)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Takahiro Noto

Sapporo Medical University, Sapporo (Japan)

0 follower

7 more presentations in this session

Research into the effect of sodium-glucose linked transporter inhibition in left ventricular remodelling in patients with heart failure and diabetes mellitus.

Speaker: Professor C. Lang (Dundee, GB)

Diminished response to statin therapy predicts future occurrence of heart failure in patients with acute myocardial infarction

Speaker: Doctor K. Tsuda (Takatsuki, JP)

Titration patterns and clinical characteristics of patients prescribed sacubitril/valsartan in the primary care and cardiology settings in germany

Speaker: Associate Professor R. Wachter (Leipzig, DE)

Characteristics of heart failure patients treated with Sacubitril - Valsartan in Europe. Results from ARIADNE

Speaker: Professor U. Zeymer (Ludwigshafen, DE)

Heart rate reduction by selective sinus node blocker (ivabradine) protects against detrimental hemodynamic and structural effects of iv inotrops in heart failure

Speaker: Professor P. Leszek (Warsaw, PL)

Access the full session

Poster Session 1 - Chronic heart failure – Treatment

Speakers: Doctor T. Noto, Professor C. Lang, Doctor K. Tsuda, Associate Professor R. Wachter, Professor U. Zeymer...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources